Conjugated vaccine against Streptococcus pneumoniae

Clinical trials.

The candidate vaccine conjugated against Streptococcus pneumoniae called QUIMI-VIO®, was developed following the approach of achieving the greatest possible relationship between impact and cost-effectiveness with the objective of being used in Cuba and in other countries. The number of serotypes remained at 7, unlike the strategy of the current conjugate vaccines but with a selection of the serotypes of greater circulation: 6B, 14, 18C, 19F, 23F, 1 and 5. In addition, a high degree of cross protection for serotypes 6A and 19A. Our strategy allows a global vaccination coverage of 75% with a more attractive price in relation to other conjugated vaccines existing in the market.